Gourgioti Rania

Gourgioti Rania

Auto-generated profile, based on publicly available information

Gourgioti Rania

CNS Department, Genesis Pharma SA, Athens, Greece

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
DEDardiotis Efthimios
Dardiotis Efthimios
KGKarachalios Georgios
Karachalios Georgios
AAAlexopoulou Antonia
Alexopoulou Antonia
GRGourgioti Rania
Gourgioti Rania
EMEvangelopoulos Maria-Eleutheria
Evangelopoulos Maria-Eleutheria
TGTOPICS Study Group
TOPICS Study Group
Background and Objectives For chronic diseases like multiple sclerosis (MS), real-world evidence on long-term treatment outcomes is essential. The study aimed to provide long-term data on the safety and effectiveness of natalizumab in patients with relapsing-remitting MS (RRMS) treated in a routine care setting in Greece. Methods TOPICS Greece was a multicenter, single-country, prospective 5-year observational study. Results Between 19-Apr-2012 and 18-Dec-2014, 304 eligible adults [females: 63.2%; median age at natalizumab initiation: 38.0 years; median disease duration: 6.2 years; median Expanded Disability Status Scale (EDSS) score at baseline: 3.5] were enrolled in the study by 20 hospital-based neurologists. The 1-year annualized relapse rate (ARR) before treatment initiation was 1.859, while the ARR during the first year of treatment was 0.131, representing a significant 93% reduction (p < 0.001). The ARR over the median treatment period of 59.4 months was 0.109. Patients with ≤1 relapse in the pre-natalizumab year (46.1%) and those having received ≤1 prior disease-modifying therapy (57.9%) displayed significantly lower on-natalizumab ARR. The 1-, 2-, 3-, 4- and 5-year cumulative probabilities of EDSS progression were 3.2, 6.2, 9.7, 13.4, and 17.4%, respectively; the respective probabilities of EDSS disability improvement were 18.3, 25.1, 27.4, 28.0, and 30.1%. Over a median safety data collection period of 48.7 months, 4.6% of the patients experienced ≥ 1 serious adverse event, with infections (reported in 1.0%) being the most common. Conclusion In real-world settings in Greece, natalizumab displayed beneficial long-term effects on disease activity and disability progression consistent with previous studies with no new serious safety signals emerging.

29 July 2021 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
PKPanagiotis Karanasios
Panagiotis Karanasios
GKGeorgios Karachalios
Georgios Karachalios
RGRania Gourgioti
Rania Gourgioti
AAAntonia Alexopoulou
Antonia Alexopoulou
VMVasileios C Mastorodemos
Vasileios C Mastorodemos
Background: Natalizumab is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS). Objective: To assess the real-world long-term safety of natalizumab in RRMS. Methods: This multicenter, 5-year prospective observational study, included adults with RRMS newly initiated on natalizumab as per the approved product label in the routine care in Greece. Safety was evaluated by collecting serious adverse events (SAEs) following study enrollment. Results: Between 19-Apr-2012 and 18-Dec-2014, 304 eligible patients (median age at natalizumab initiation: 38.0 years; median disease duration: 6.2 years) were enrolled by 20 hospital-based neurologists. Over a median treatment duration period of 58.7 months, 50.7% of the patients discontinued natalizumab, mainly due to anti-JCV antibody detection (59.1%). The adverse event treatment discontinuation rate was 5.2%. The SAE incidence rate during the safety data collection period (median: 48.7 months) was 4.6%. The most common SAEs were infections (1.0%), including 2 cases (0.7%) of progressive multifocal leukoencephalopathy (PML), and no other opportunistic infections. PML diagnoses occurred 6.2-6.7 years after natalizumab initiation, and approximately 2 years after first detection of anti-JCV antibody for both patients. The incidence rate of malignancies was 0.7%. Conclusion: In real-world settings in Greece, natalizumab displayed an acceptable safety profile, with no new safety signals emerging.